Ardelyx Inc (ARDX)
6.43
+0.04
(+0.63%)
USD |
NASDAQ |
Apr 24, 16:00
6.435
0.00 (0.00%)
After-Hours: 20:00
Ardelyx Cash from Operations (TTM): -89.72M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -89.72M |
September 30, 2023 | -66.72M |
June 30, 2023 | -70.68M |
March 31, 2023 | -87.22M |
December 31, 2022 | -70.04M |
September 30, 2022 | -123.80M |
June 30, 2022 | -132.96M |
March 31, 2022 | -135.95M |
December 31, 2021 | -152.55M |
September 30, 2021 | -130.67M |
June 30, 2021 | -115.96M |
March 31, 2021 | -100.71M |
December 31, 2020 | -81.44M |
September 30, 2020 | -74.98M |
June 30, 2020 | -75.72M |
March 31, 2020 | -84.52M |
December 31, 2019 | -76.48M |
September 30, 2019 | -83.78M |
June 30, 2019 | -90.19M |
March 31, 2019 | -80.38M |
December 31, 2018 | -70.27M |
Date | Value |
---|---|
September 30, 2018 | -47.14M |
June 30, 2018 | -39.36M |
March 31, 2018 | -45.23M |
December 31, 2017 | -65.19M |
September 30, 2017 | -96.64M |
June 30, 2017 | -102.03M |
March 31, 2017 | -103.05M |
December 31, 2016 | -92.53M |
September 30, 2016 | -87.39M |
June 30, 2016 | -74.56M |
March 31, 2016 | -79.88M |
December 31, 2015 | -71.84M |
September 30, 2015 | -54.03M |
June 30, 2015 | -47.91M |
March 31, 2015 | 6.308M |
December 31, 2014 | 13.40M |
September 30, 2014 | 28.10M |
June 30, 2014 | 33.58M |
March 31, 2014 | 4.816M |
December 31, 2013 | 1.811M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-152.55M
Minimum
Dec 2021
-66.72M
Maximum
Sep 2023
-97.06M
Average
-87.22M
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
Nektar Therapeutics | -192.61M |
Omeros Corp | 74.73M |
Vistagen Therapeutics Inc | -26.09M |
Karyopharm Therapeutics Inc | -92.72M |
Adverum Biotechnologies Inc | -90.90M |